People: Abaxis Inc (ABAX.O)
45.35USD
17 May 2013
$-0.10 (-0.22%)
$45.45
$45.56
$45.70
$44.94
149,817
159,221
$49.45
$31.04
Aron, Kenneth
Brief Biography
Dr. Kenneth P. Aron, Ph.D., is Chief Technology Officer of Abaxis Inc., since April 2008. Dr. Aron joined the company in February 2000 as Vice President of Research and Development. From April 1998 to November 1999, Dr. Aron was Vice President of Engineering and Technology of Incyte Pharmaceuticals (Nasdaq: INCY), a genomic information company. From April 1996 to April 1998, Dr. Aron was Vice President of Research, Development and Engineering for Cardiogenesis Corporation (Nasdaq: CGCP), a manufacturer of laser-based cardiology surgical products.
Basic Compensation
| Total Annual Compensation, USD | Long-Term Incentive Plans, USD | All Other, USD | Fiscal Year Total, USD |
|---|---|---|---|
| 413,839 | -- | 23,502 | 1,152,340 |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | 233,667 | 3,284,000.00 |
| Unexercisable | 10,833 | 204,000.00 |
| Excercised | 45,125 | 768,469.00 |
| Name | Fiscal Year Total |
|---|---|
Clinton Severson |
2,302,420 |
Alberto Santa Ines |
1,129,370 |
Donald Wood |
1,137,100 |
Kenneth Aron |
1,152,340 |
Brenton Hanlon |
-- |
Vladimir Ostoich |
1,147,460 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
